<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Long QT eight (LQT8), otherwise known as Timothy syndrome (TS), is a <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic disorder</z:e> causing hyper-activation of the L-type calcium channel Cav 1.2 </plain></SENT>
<SENT sid="1" pm="."><plain>This calcium load and the resultant increase in the QT interval provide the substrate for <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We previously presented a case in a patient with TS who had a profound decrease in his burden of <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> after institution of an L-type <z:chebi fb="1" ids="38215">calcium channel blocker</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Although this patient's <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> burden had decreased, he displayed an increasing burden of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> and still had bouts of <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> requiring defibrillator therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Basic research has recently shown that ranolazine, a multipotent ion-channel blocker, may be of benefit in patients with LQT8 syndrome </plain></SENT>
<SENT sid="5" pm="."><plain>This case report details the decrease of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> and <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> events in our LQT8 patient with the addition of ranolazine </plain></SENT>
</text></document>